Orent Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.50 M
- Company Age 20 Year, 2 Months
- Last Filing with ROC 31 Mar 2012
- Open Charges ₹ 1.60 M
About Orent Pharmaceuticals
Orent Pharmaceuticals Private Limited (OPPL) is a Private Limited Indian Non-Government Company incorporated in India on 03 December 2004 and has a history of 20 years and two months. Its registered office is in Ranchi, Jharkhand.
The Company is engaged in the Home Appliances Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2012. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹1.60 M.
Aditya Kumar, Pradip Kumar, Ranjana Prasad, and One other member serve as directors at the Company.
Company Details
- Location Ranchi, Jharkhand
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U51397JH2004PTC011048
- Company No.
011048
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Dec 2004
- Date of AGM
29 Sep 2012
- Date of Balance Sheet
31 Mar 2012
- Listing Status
Unlisted
- ROC Code
Roc Jharkhand
Industry
Who are the key members and board of directors at Orent Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pradip Kumar  | Managing Director | 03-Dec-2004 | Current |
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Aditya Kumar | Director | 06-Mar-2007 | Current |
| Ranjana Prasad | Director | 03-Dec-2004 | Current |
| Ram Prasad | Director | 15-Feb-2006 | Current |
Financial Performance of Orent Pharmaceuticals.
Enhance accessibility to Orent Pharmaceuticals's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Orent Pharmaceuticals?
Unlock access to Orent Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹1.60 M
₹0
Charges Breakdown by Lending Institutions
- Bank Of India : 0.16 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 04 Nov 2006 | Bank Of India | ₹1.60 M | Open |
How Many Employees Work at Orent Pharmaceuticals?
Unlock and access historical data on people associated with Orent Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Orent Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Orent Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.